Next Article in Journal
Ondansetron Rapidly Dissolving Film for the Prophylactic Treatment of Radiation-Induced Nausea and Vomiting—A Pilot Study
Previous Article in Journal
Comparing Effectiveness with Efficacy: Outcomes of Palliative Chemotherapy for Non-Small-Cell Lung Cancer in Routine Practice
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 22
Issue 3
10.3747/co.22.2284
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Using Proliferative Markers and Oncotype Dx in Therapeutic Decision-Making for Breast Cancer: The B.C. Experience

by
E. Baxter
1,*,
L. Gondara
2,
C. Lohrisch
3,
S. Chia
3,
K. Gelmon
3,
M. Hayes
4,
A. Davidson
3 and
S. Tyldesley
1
1
Department of Radiation Oncology, BC Cancer Agency, Vancouver Centre, BC, Canada
2
Department of Cancer Surveillance and Outcomes, BC Cancer Agency, Vancouver Centre, BC, Canada
3
Department of Medical Oncology, BC Cancer Agency, Vancouver Centre, BC, Canada
4
Department of Pathology, BC Cancer Agency, Vancouver Centre, BC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2015, 22(3), 192-198; https://doi.org/10.3747/co.22.2284
Submission received: 12 March 2015 / Revised: 11 April 2015 / Accepted: 13 May 2015 / Published: 1 June 2015

Abstract

Background: Proliferative scoring of breast tumours can guide treatment recommendations, particularly for estrogen receptor (ER)–positive, HER2-negative, T1–2, N0 disease. Our objectives were to (1) estimate the proportion of such patients for whom proliferative indices [mitotic count (MC), Ki-67 immunostain, and Oncotype DX (Genomic Health, Redwood City, CA, U.S.A.) recurrence score (RS)] were obtained; (2) compare the indices preferred by oncologists with the indices available to them; (3) correlate Nottingham grade (NG) and its subcomponents with Oncotype DX; (4) assess interobserver variation. Methods: All of the ER-positive, HER2-negative, T1–2, N0 breast cancers diagnosed from 2007 to 2011 (n = 5110) were linked to a dataset of all provincial breast cancers with a RS. A 5% random sample of the 5110 cancers was reviewed to estimate the proportion that had a MC, Ki-67 index, and RS. Correlation coefficients were calculated for the RS with NG subcomponent scores. Interobserver variation in histologic grading between outside and central review pathology reports was assessed using a weighted kappa test. Results: During 2007–2011, most cancers were histologically graded and assigned a MC; few had a Ki-67 index or RS. The NG and MC were significantly positively correlated with RS. The level of agreement in histologic scoring between outside and central pathology reports was good or very good. Very few cases with a low MC had a high RS (1.8%). Conclusions: Patients with low NG and MC scores are unlikely to have a high RS, and thus are less likely to benefit from chemotherapy. In the context of limited resources, that finding can guide clinicians about when a RS adds the most value.
Keywords: breast cancer; proliferative markers breast cancer; proliferative markers

Share and Cite

MDPI and ACS Style

Baxter, E.; Gondara, L.; Lohrisch, C.; Chia, S.; Gelmon, K.; Hayes, M.; Davidson, A.; Tyldesley, S. Using Proliferative Markers and Oncotype Dx in Therapeutic Decision-Making for Breast Cancer: The B.C. Experience. Curr. Oncol. 2015, 22, 192-198. https://doi.org/10.3747/co.22.2284

AMA Style

Baxter E, Gondara L, Lohrisch C, Chia S, Gelmon K, Hayes M, Davidson A, Tyldesley S. Using Proliferative Markers and Oncotype Dx in Therapeutic Decision-Making for Breast Cancer: The B.C. Experience. Current Oncology. 2015; 22(3):192-198. https://doi.org/10.3747/co.22.2284

Chicago/Turabian Style

Baxter, E., L. Gondara, C. Lohrisch, S. Chia, K. Gelmon, M. Hayes, A. Davidson, and S. Tyldesley. 2015. "Using Proliferative Markers and Oncotype Dx in Therapeutic Decision-Making for Breast Cancer: The B.C. Experience" Current Oncology 22, no. 3: 192-198. https://doi.org/10.3747/co.22.2284

APA Style

Baxter, E., Gondara, L., Lohrisch, C., Chia, S., Gelmon, K., Hayes, M., Davidson, A., & Tyldesley, S. (2015). Using Proliferative Markers and Oncotype Dx in Therapeutic Decision-Making for Breast Cancer: The B.C. Experience. Current Oncology, 22(3), 192-198. https://doi.org/10.3747/co.22.2284

Article Metrics

Back to TopTop